The relevance of therapeutic drug monitoring (TDM) and pharmacogenetics in studies about drug safety in psychiatry;Bedeutung von TDM und pharmakogenetik bei untersuchungen über arzneimittelsicherheit in der psychiatrie

Psychopharmakotherapie

Volumn 10, Issue 1, 2003, Pages 5-10

  Jaquenoud Sirot, Eveline ^b   Eap, Chin B ^a   Baumann, Pierre ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b MediQ   (Switzerland)

Author keywords

AMSP; Cytochrome P 450; Pharmacogenetics; Pharmacovigilance; Psychotropic drugs; Therapeutic drug monitoring

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 2D6; HALOPERIDOL; NEUROLEPTIC AGENT; NORTRIPTYLINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

CLINICAL TRIAL; COMORBIDITY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; GENOTYPE; HOSPITAL PATIENT; HUMAN; MENTAL DISEASE; MENTAL PATIENT; META ANALYSIS; PHARMACOGENETICS; PHENOTYPE; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; REVIEW; SIDE EFFECT;

EID: 0037327784     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Bates DW, Spell N, Cullen DJ, Burdick E, et al. The costs of adverse drug events in hospitalised patients. JAMA 1997;277:307-11.
2. Baumann P, Kosel M, Voirol P. Pharmakogenetische Charakterisierung - Pharmakogenetik in der Psychopharmakologie. In: Gastpar M, Banger M (Hrsg.). Laboruntersuchungen in der psychiatrischen Routine. Stuttgart: Georg Thieme Verlag, 2000:134-49.
3. Baumann P, Zullino D, Eap CB. Pharmakokinetik und therapeutisches Monitoring von Antidepressiva. In: Laux G (Hrsg.). Depression 2000. Berlin: Springer-Verlag, 2002:37-50.
4. Baumann P, Zullino DF, Jaquenoud Sirot E, Paus E, et al. Therapy with antidepressants: pharmacogenetic aspects. In: Kaschka (ed): Perspectives in Affective Disorders. Adv Biol Psychiatry, Vol. 21. Basel: Karger, 2002:95-111.
5. rd ed. Paris: Flammarion, Médecine-Sciences 1999:127-48.
6. Bégaud B. Pharmacovigilance. In: Bégaud B. (ed.). Dictionary of pharmacoepidemiology. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley & Sons Ltd., 2000:109.
7. Bender S, Eap CB. Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry 1998;55:1048-50.
8. Bender S, Grohmann R, Engel R, Hippius H, et al. Arzneimittelsicherheit in der Psychiatrie (AMSP). Qualitätssicherung in der Psychopharmakotherapie: das AMSP-Projekt. Psycho 2001;27:198-204.
9. Bertilsson L, Dahl ML, Dalen P, Al Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-22.
10. Bonnabry P, Sievering J, Leeman T, Dayer P. Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. Clin Pharmakokinet 2001;40:631-40.
11. Brockmöller J, Cascorbi I, Kerb R, Sachse C, et al. Polymorphisms in xenobiotic conjugation and disease predisposition. Toxicol Lett 1998;102-103:173-83.
12. Burchell B. Transformation reactions: glucuronidation. In: Woolf TF (editor). Handbook of drug metabolism. New York: Marcel Dekker, Inc., 1999:153-73.
13. Buur-Rasmussen B, Brøsen K. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol 1999;9:453-9.
14. Ciraulo DA, Shader RI, Greenblatt DJ, Barnhill JG. Basic concepts. In: Ciraulo DA, Shader RI, Greenblatt DJ, Creelman WL (editors). Drug interactions in psychiatry. Maryland, USA: Williams & Wilkins, 1995:1-28.
15. Collette D, Thurmann PA. Unerwünschte Arzneimittelwirkungen - Erbliche Unterschiede im Arzneistoffmetabolismus. Dtsch Med Wochenschr 2002;127:1025-8.
16. Conus P, Bondolfi G, Eap CB, Macciardi F, et al. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patients. Pharmacopsychiatry 1996;29:108-10.
17. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002;41:453-70.
18. Doherty MM, Charman WN. The mucosa of the small intestine - How clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 2002;41:235-53.
19. th ed. Amstedam/New York: Elsevier, 2000.
20. Ensom MHH, Chang TKH, Patel P. Pharmacogenetics - The therapeutic drug monitoring of the future? Clin Pharmacokinet 2001;40:783-802.
21. Ghersi-Egea JF, Strazielle N. Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus. Microsc Res Tech 2001;52:83-8.
22. Grohmann R, Rüther E, Engel RR, Hippius H. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP Drug Safety Program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatry 1999;32:21-8.
23. Gundert-Remy U. Pharmakologische Grundlagen von UAWs. In: Müller-Oerlinghausen B, Lasek R, Düppenbecker H, Munter K-H (Eds). Handbuch der unerwünschten Arzneimittelwirkungen. München: Urban & Fischer, 1999;4:620-6.
24. Haffen E, Vandel P, Broly F, Vandel S, et al. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype. Pharmacopsychiatry 1999;32:232-4.
25. Hiemke C, Härtter S, Weigmann H. Therapeutisches Drug Monitoring (TDM). In: Gastpar M, Banger M (editors). Laboruntersuchungen in der psychiatrischen Routine. Stuttgart: Georg Thieme Verlag, 2000:106-33.
26. Hiemke C, Weigmann H, Härtter S, Mann K. Therapeutisches Drug Monitoring von Psychopharmaka. Neurotransmitter 2000;11:52-5.
27. Jaquenoud Sirot E, Zullino D. Guide to combination therapy in psychiatry with special emphasis on fluvoxamine. Hannoversche Aerzte-Verlags-Union, 2000.
28. Kirchheiner J, Brøsen K, Dahl ML, Gram LF, et al. CYP2D6 and CYP2C 19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104:173-92.
29. Lazarou J, Pomeranz BH, Corey PN, Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998;279:1200-4.
30. Linnet K, Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997;25:1379-82.
31. Liston HL, Markowitz JS, DeVane CL. Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 2001;21:500-15.
32. Mancama D, Arranz MJ, Kerwin RW. Genetic predictors of therapeutic response to clozapine - Current status of research. CNS Drugs 2002;16:317-24.
33. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667-71.
34. Müller-Oerlinghausen B, Lasek R, Düppenbecker H, Munter KH (Eds). Handbuch der unerwünschten Arzneimittelwirkungen. München: Urban & Fischer, 1999.
35. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995;152:173-8.
36. Pabel HJ, Beckmann J, Munter KH, Dinnendahl V, et al. Abwehr von Arzneimittelrisiken. In: Müller-Oerlinghausen B, Lasek R, Düppenbecker H, Munter K-H (Eds). Handbuch der unerwünschten Arzneimittelwirkungen. München: Urban & Fischer, 1999;1:549-92.
37. Preskorn SH, Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA 1997;277:1682.
38. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002;315:137-55.
39. Stephens MDB. Pharmacovigilance: introduction. In: Stephens MDB, Talbot JCC, Routlege PA (editors). Detection of new adverse drug reactions. New York: Grove's Dictionaries Inc., 1998:1-57.
40. rd edition. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley & Sons Ltd., 2001.
41. Zullino DF, Horvath A, Greil W, Grohmann R, et al. Die Bedeutung der Pharmakovigilanz in der Psychiatrie: das AMSP-Projekt (Arzneimittelsicherheit in der Psychiatrie). Schweizer Archiv für Neurologie und Psychiatrie 2002;153:266-71.